scandinavianstock-shutterstock-com

SCANDINAVIANSTOCK / SHUTTERSTOCK.COM

1 June 2016Big Pharma

SPCs: a state of conflict

When the Court of Justice of the European Union (CJEU) hands down its judgments, it often feels like a double-edged sword for European-based intellectual property practitioners.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

GSK triumphs in EPO appeal, revoking Pfizer patent

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

Teva fights for re-listing of inhaler patents at US appeals court

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m